Expand all sections

Benralizumab

Fasenra

Extended indication Extension of indication to include treatment of eosinophilic granulomatosis.
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Benralizumab
Domain Lung diseases
Reason of inclusion Indication extension
Main indication Lung diseases other
Extended indication Extension of indication to include treatment of eosinophilic granulomatosis.
Proprietary name Fasenra
Manufacturer AstraZeneca
Portfolio holder AstraZeneca
Mechanism of action Interleukin inhibitor
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date December 2023
Expected Registration October 2024
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet
References NCT04157348

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.